Precision Oncology Conferences

Our conferences distill the latest precision oncology advances enabling you to accelerate the development of more effective cancer treatments for targeted patient populations.

Covering the breadth of precision oncology drug development, our sector-defining conferences on ADCs, targeted radiopharmaceuticals, companion diagnostics, and bispecifics provide the insight you need to deliver more effective treatments for patients in need.

0

11th Tumor Models Boston

July 2023

Enhance Predictability & Translatability of Novel Combination Targeted Therapies

Precision Oncology

Conference

13th World Clinical Biomarkers & CDx Boston

September 2023

Supercharging Development, Approval & Commercialization of Next Generation Companion Diagnostics

Precision Oncology

Conference

mRNA Cancer Vaccine Summit

October 2023

Supercharging Individualized Vaccine & Cell Based Immunotherapies

Precision Oncology

Conference

2nd LBx Surveillance & Early Detection Summit

November 2023

Recognizing Disease Hallmarks Earlier for Improved Patient Outcomes

Precision Oncology

Conference

Tumour Models London

December 2023

Engineering Your Next Generation Tumour Models to Maximise Clinical Success

Precision Oncology

Conference

8th Oncolytic Virotherapy Summit

December 2023

Weaponize Oncolytic Viruses to Generate Robust Anti-Tumor Immunity

Precision Oncology

Conference

– 14th Clinical Biomarkers & CDx Europe

April 2024

Fast-Tracking Clinical Biomarker & CDx Development in Oncology & Inflammatory Diseases

Precision Oncology

View and search all of our conferences.

View All Conferences

Accelerating the Development of More Efficacious Precision Oncology Therapeutics

Testimonials

“I’m looking forward to attending and presenting at the World Clinical Biomarkers & CDx Summit. This is a key meeting for researchers, biomarker developers and Pharma to connect and shape the future of Precision Medicine.”

Amy Gorman

Director, Global Commercial Strategy, Precision Medicine, Janssen

“This conference has been very insightful in the past as the field of CDx is still advancing and we can learn from each other’s experiences.”

Silva Krause

Senior Director, Clinical Biomarkers, Vertex Pharmaceuticals

“Very rewarding. Resulted in several big pharma collaborations.”

Co-Founder & CEO, Aracari Biosciences

“Really enjoyed the conference. Great integration with speakers and delegates. The small size made it easier to make connections. Overall, the quality of the speakers and delegates was very high. I would definitely recommend it and hope to return next year.”

Group Lead, Gamma Delta Therapeutics